Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

ESR1 mutations in metastatic lobular breast cancer patients.

Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C.

NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019.

2.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC.

Nat Commun. 2018 Mar 1;9(1):896. doi: 10.1038/s41467-018-03215-x.

3.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M.

Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y.

4.

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.

Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner N.

Ann Oncol. 2018 Jan 1;29(1):145-153. doi: 10.1093/annonc/mdx483.

5.

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC.

Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.

6.

Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.

Hrebien S, O'Leary B, Beaney M, Schiavon G, Fribbens C, Bhambra A, Johnson R, Garcia-Murillas I, Turner N.

PLoS One. 2016 Oct 19;11(10):e0165023. doi: 10.1371/journal.pone.0165023. eCollection 2016.

7.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC.

J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.

PMID:
27269946
8.

Management of breast cancer in older and frail patients.

Smith IE, Fribbens C.

Breast. 2015 Nov;24 Suppl 2:S159-62. doi: 10.1016/j.breast.2015.07.037. Epub 2015 Aug 21.

PMID:
26303987
9.

The hypothalamic mechanisms of the hypophysiotropic action of ghrelin.

Wren AM, Small CJ, Fribbens CV, Neary NM, Ward HL, Seal LJ, Ghatei MA, Bloom SR.

Neuroendocrinology. 2002 Nov;76(5):316-24.

PMID:
12457042

Supplemental Content

Loading ...
Support Center